The Success of Mifepristone and Misoprostol in the Management of Early Pregnancy Loss at a Community Hospital: A Prospective Study

J Obstet Gynaecol Can. 2024 Sep;46(9):102604. doi: 10.1016/j.jogc.2024.102604. Epub 2024 Jun 29.

Abstract

Objectives: This prospective single-arm study was conducted to understand the expulsion rate of the gestational sac in the management of early pregnancy loss (EPL).

Methods: We recruited 441 participants; 188 met the eligibility criteria. Participants were 18 years of age and older who experienced a confirmed EPL (<12 weeks gestational age) defined by an intrauterine pregnancy with a non-viable embryonic or anembryonic gestational sac with no fetal heart activity. Participants were given 200 mg of mifepristone pre-treatment orally followed by 2 doses of misoprostol 800 μg vaginally after 24 and 48 hours. Participants were seen in follow-up on day 14 to confirm the absence of a gestational sac, classified as treatment success. For failed treatment (defined by retained gestational sac), we offered expectant management or a third dose of misoprostol and/or dilatation and curettage. We followed all participants for 30 days. We collected data on overtreatment for retained products of conception and hospital admissions for adverse events.

Results: Overall, 181 participants followed the protocol and 169 (93.3%) participants had a complete expulsion of the gestational sac by the second visit (day 14). Twelve (6.6%) failed the treatment and 1 had an adverse event of heavy vaginal bleeding requiring dilatation and curettage. Despite the expulsion of the gestational sac, 29 cases (17.1%) at subsequent follow-up were diagnosed as retained products of conception based on ultrasound assessment of thickened endometrium.

Conclusions: Pretreatment with mifepristone followed by 2 doses of misoprostol with a 14-day follow-up resulted in a high expulsion rate and is a safe management option for EPL.

Keywords: abortion; early pregnancy loss; incomplete abortion; miscarriage; missed abortion; pregnancy loss.

MeSH terms

  • Abortifacient Agents, Nonsteroidal* / administration & dosage
  • Abortifacient Agents, Nonsteroidal* / therapeutic use
  • Abortifacient Agents, Steroidal / administration & dosage
  • Abortifacient Agents, Steroidal / therapeutic use
  • Abortion, Spontaneous*
  • Adult
  • Female
  • Hospitals, Community
  • Humans
  • Mifepristone* / administration & dosage
  • Mifepristone* / therapeutic use
  • Misoprostol* / administration & dosage
  • Misoprostol* / therapeutic use
  • Pregnancy
  • Prospective Studies
  • Treatment Outcome
  • Young Adult

Substances

  • Mifepristone
  • Misoprostol
  • Abortifacient Agents, Nonsteroidal
  • Abortifacient Agents, Steroidal